How long does losing 40 pounds on Wegovy actually take?

The myth worth correcting: a fixed number of months

The most common misconception is that there is a standard Wegovy timeline (twelve weeks for one person, twelve months for another) and that slow progress means the medicine is not working. That framing is wrong, and it causes people to stop treatment prematurely.

What clinical evidence actually shows is a curve, not a countdown. The STEP 1 trial, published in the New England Journal of Medicine, followed nearly 2,000 adults on 2.4 mg semaglutide for 68 weeks. Average weight loss was around 15% of starting body weight. For someone at 120 kg (about 265 lb), that is 18 kg, almost exactly 40 pounds. But the shape of that loss matters: most of it happened in the first 32 weeks, with progress slowing markedly after that as the body adapts.

A 40-pound target sits at roughly the 15% mark for a person starting at around 120 kg, and well below it for someone starting heavier. If your starting weight is 160 kg, 40 pounds is less than 12% of body weight and often achievable within six to nine months at maintenance dose. Starting lighter means 40 pounds is a proportionally larger loss and will take longer. The arithmetic matters more than any generic promise.

How the titration schedule shapes when results arrive

Wegovy does not start at its full maintenance dose. Treatment begins at 0.25 mg weekly and steps up approximately every four weeks: 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. Reaching maintenance takes around sixteen weeks. During titration, appetite suppression is real but partial, and weight loss during that phase is typically slower than what follows.

This is worth understanding in practical terms. By the time a pen goes into the fridge door for the first time, the clock has started, but the full appetite-suppressing effect of maintenance-dose semaglutide builds gradually over those four months. People who expect dramatic early results can become discouraged at exactly the point where the medicine is still finding its ceiling.

The newer 7.2 mg Wegovy dose, approved by the MHRA in April 2026 as a dedicated single-dose pen, showed average weight loss of around 20.7% over 72 weeks in trials. For someone targeting 40 pounds, that higher dose could reduce the overall timeline if it is clinically appropriate and titrated up to it. Whether that route is right for you is a prescriber's call, not something to decide from a webpage. If you want to understand how long you may need to take Wegovy to reach your weight loss goal, that detail sits alongside the broader picture covered on the general weight loss timeline on Wegovy page.

Plateau, slowdown, and what that actually means

Around months four to six, most people notice the rate of loss easing. This is not the treatment failing. It reflects two overlapping processes: the body's metabolic adaptation to lower calorie intake, and the fact that a smaller body burns fewer calories at rest. Both are well-documented in the weight-management literature and are not unique to semaglutide.

For some people, a dose increase to the 7.2 mg pen restarts meaningful progress. For others, the maintenance phase at 2.4 mg holds their losses and prevents regain. The NHS England guidance on weight-management injections is clear that ongoing treatment review matters, and that stopping too soon frequently results in weight returning. If you are six months in and the scale has barely moved, that conversation belongs with your prescriber, not a forum.

For context on what the highest documented losses on semaglutide look like in practice, the most weight lost on Wegovy page covers the upper end of the evidence. And if your goal is larger, the 100-pound Wegovy timeline applies the same framework to a bigger target.

What actually moves the needle on your personal timeline

Three factors consistently differentiate faster from slower outcomes in the clinical data: starting body weight (heavier starting points produce larger absolute losses early on), dietary quality alongside treatment (semaglutide reduces appetite but does not make poor nutrition irrelevant), and consistency with the injection schedule. Missing doses, especially during titration, interrupts the steady-state plasma level the medicine relies on.

Beyond that, certain clinical factors change the picture: polycystic ovary syndrome, hypothyroidism, insulin resistance, and some medicines can all slow loss independently of semaglutide's action. That is why a thorough prescriber review before starting is not a formality. You can explore the evidence on how long Wegovy takes to produce early effects for more detail on the first weeks specifically.

If you are weighing up whether Wegovy or another licensed option is the better fit, our treatment overview sets out what is available. For questions about cost alongside this planning, the Wegovy cost in the UK page addresses what private treatment typically involves. When you are ready to discuss your own starting point and goals with a prescriber, check your eligibility through our free consultation.